MedTrace Logo

Filgrastim for the Promotion of Collateral Growth in Patients With CAD

NCT00596479 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-06-16

No results posted yet for this study

Summary

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

Conditions

Interventions

DRUG

Filgrastim (rG-CSF)

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Swiss Heart Foundation

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Steffen Gloekler, MD · University of Bern

  • Tobias Rutz, MD · University of Bern

  • Pascal Meier, MD · University of Bern

  • Christian Seiler, MD · University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596479 on ClinicalTrials.gov